可降胆固醇的优势乳杆菌筛选

为丰富降胆固醇、降血糖的益生菌资源,以实验室10株潜力益生菌株为实验对象,进行体外降胆固醇能力、胆盐水解酶(BSH)活性及α-葡萄糖苷酶抑制率试验,测定菌株对人工胃液和胆盐的耐受性,评价优势菌株的细胞黏附性能及对抗生素的耐药安全性能。结果表明,植物乳杆菌LH-511、植物乳杆菌10-12、植物乳杆菌10-4对胆固醇的降解率在50%以上,显著高于商业菌株植物乳杆菌299V(p<0.05)。植物乳杆菌10-12、植物乳杆菌SD-H9对α-葡萄糖苷酶的抑制率高达41.7%、40.1%。植物乳杆菌LH-511、植物乳杆菌10-12、植物乳杆菌10-4、植物乳杆菌10-14、卷曲乳杆菌OF48-2pH5这5株菌具有较好的BSH活力、α-葡萄糖苷酶抑制性、抗逆性以及对HT-29细胞的黏附能力。但仅植物乳杆菌LH-511和卷曲乳杆菌OF48-2pH5通过了10种抗生素的安全性试验。综上所述,植物乳杆菌LH-511和卷曲乳杆菌OF48-2pH5具有较好的降胆固醇、降血糖潜力,且通过了抗逆性、黏附性、安全性试验,可用于进一步的开发和应用。

Screening of Preponderant Lactobacillus for Lowering Cholesterol

In order to enrich the probiotics resources for lowering cholesterol and lowering glycemia,ten Lactobacillus strains were used as experimental subjects to test the lowering cholesterol ability,bile salt hydrolase(BSH)activity and α-glucosidase inhibition rate in vitro,as well as the tolerance to artificial gastric juice and bile salt,and then evaluate of cell adhesive capacity and tolerance to antibiotics of dominant strains. The results showed that the degradation of cholesterol by Lactobacillus plantarum LH-511,Lactobacillus plantarum 10-12 and Lactobacillus plantarum 10-4 was above 50%,which was significantly higher than that of the commercial strain Lactobacillus plantarum 299V(p<0.05). The inhibition rate of Lactobacillus plantarum 10-12 and Lactobacillus plantarum SD-H9 to α-glucoside was 41.7% and 40.1%. Lactobacillus plantarum LH-511,Lactobacillus plantarum 10-12,Lactobacillus plantarum 10-4,Lactobacillus plantarum 10-14 and Lactobacillus casei OF48-2pH5 have preferable BSH activity,α-glucosidase inhibition,stress resistance and adhesion to HT-29 cell. However,only Lactobacillus plantarum LH-511 and Lactobacillus crispus OF48-2 pH5 passed the safety test of 10 antibiotics. In summary,Lactobacillus plantarum LH-511 and Lactobacillus casei OF48-2pH5 had good cholesterol-lowering and glycemia-lowering potential,and had passed the test of stress resistance,adhesion and safety,which can be used for further development and application.